|
|
||||||||


* Institute for Genetics, University of Cologne, and
Klinik II und Poliklinik für Innere Medizin der Universität zu Koeln and Center of Molecular Medicine, Cologne, Germany; and
Department of Pathology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814
The IGF-1 receptor (IGF-1R) is expressed on T and B lymphocytes, and the expression of the insulin- and IGF-1-signaling machinery undergoes defined changes throughout lineage differentiation, offering a putative role for IGF-1 in the regulation of immune responses. To study the role of the IGF-1R in lymphocyte differentiation and function in vivo, we have reconstituted immunodeficient RAG2-deficient mice with IGF-1R/ fetal liver cells. Despite the absence of IGF-1Rs, the development and ex vivo activation of B and T lymphocytes were unaltered in these chimeric mice. By contrast, the humoral immune response to the T cell-independent type 2 Ag 4-hydroxy-3-nitrophenyl acetyl-Ficoll was significantly reduced in mice reconstituted with IGF-1R-deficient fetal liver cells, whereas responses to the T cell-dependent Ag 4-hydroxy-3-nitrophenyl acetyl-chicken globulin were normal. Moreover, in an in vitro model of T cell-independent type 2 responses, IGF-1 promoted Ig production potently upon polyvalent membrane-IgD cross-linking. These data indicate that functional IGF-1R signaling is required for T cell-independent B cell responses in vivo, defining a novel regulatory mechanism for the immune response against bacterial polysaccharides.
This article has been cited by other articles:
![]() |
R. S. Douglas, V. Naik, C. J. Hwang, N. F. Afifiyan, A. G. Gianoukakis, D. Sand, S. Kamat, and T. J. Smith B Cells from Patients with Graves' Disease Aberrantly Express the IGF-1 Receptor: Implications for Disease Pathogenesis J. Immunol., October 15, 2008; 181(8): 5768 - 5774. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kucic, I. B. Copland, J. Cuerquis, D. L. Coutu, L. E. Chalifour, R. F. Gagnon, and J. Galipeau Mesenchymal stromal cells genetically engineered to overexpress IGF-I enhance cell-based gene therapy of renal failure-induced anemia Am J Physiol Renal Physiol, August 1, 2008; 295(2): F488 - F496. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Douglas, A. G. Gianoukakis, S. Kamat, and T. J. Smith Aberrant Expression of the Insulin-Like Growth Factor-1 Receptor by T Cells from Patients with Graves' Disease May Carry Functional Consequences for Disease Pathogenesis J. Immunol., March 1, 2007; 178(5): 3281 - 3287. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Hansenne, C. Renard-Charlet, R. Greimers, and V. Geenen Dendritic cell differentiation and immune tolerance to insulin-related peptides in igf2-deficient mice. J. Immunol., April 15, 2006; 176(8): 4651 - 4657. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |